StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) income statement

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.37−0.06 (-4.20%)

Close on Nov 18, 2026Market cap $32.61MP/E –Yield –

Kalaris Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin
–
Operating margin
–
Net margin
–
Return on equity, FY2025
488.0%

Financial strength

Current ratio
10.98
Debt to equity
–
Debt to assets
–
Cash to current liabilities
494.1%

Valuation

P/E ratio
–
Price to sales
–
Price to book
0.57
Dividend yield
–

See a number that looks wrong?